Innoviva, Inc. filings document a Nasdaq-listed common-stock issuer with a royalty healthcare portfolio, Innoviva Specialty Therapeutics operations, and strategic healthcare investments. Form 8-K reports furnish operating results and financial condition, including royalty revenue, IST net product sales, product-portfolio developments, fair-value changes in investments, and capital allocation activity.
Proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, and equity incentive plan approvals. The record also identifies the company’s common stock, par value $0.01 per share, traded under INVA on the Nasdaq Global Select Market.
Innoviva, Inc. (INVA) reported nine-month 2026 revenue of $323.705 million, compared with $296.715 million in 2025, while net income was $29.287 million versus $107.012 million. For the quarter ended September 30, revenue was $106.120 million versus $107.800 million, and Innoviva recorded a $73.888 million net loss compared with $89.908 million net income a year earlier. Quarterly results included fair-value losses of $97.585 million on equity-method investments and $41.904 million on equity and long-term investments.
Nine-month net product sales were $142.586 million, versus $113.066 million, while royalty revenue was $166.158 million versus $181.583 million. Operating cash flow was $128.952 million, compared with $142.417 million; cash and cash equivalents were $581.394 million as of September 30, 2026.
During the nine months ended September 30, Innoviva repurchased 3,601,261 shares at an average $21.70 per share for approximately $78.2 million. It repurchased another 454,835 shares for approximately $9.6 million through October 31, 2026. Its program authorizes repurchases up to $125.0 million; all repurchased shares were retired.
Innoviva, Inc. (INVA) reported third-quarter 2026 revenue of $106.1 million and a net loss of $73.9 million. Revenue compared with $107.8 million and net income with $89.9 million in the third quarter of 2025. Net royalty revenue was $54.7 million, versus $59.9 million a year earlier, while income from operations was $42.2 million, compared with $34.6 million. Changes in fair values included losses of $97.6 million on equity method investments and $41.9 million on equity and long-term investments.
U.S. net product sales were $43.3 million, up 45% year over year. Chief Executive Officer Pavel Raifeld said the company remained on track for 2026 U.S. net product sales of at least $150 million. Innoviva repurchased 1.2 million shares during Q3 under its $125 million buyback program, and NUZOLVENCE became commercially available in the U.S. Cash and cash equivalents totaled $581.4 million as of September 30, 2026. Operating cash flow for the first nine months was $129.0 million, versus $142.4 million in 2025.
BlackRock, Inc. reported beneficial ownership of 11,138,961 Innoviva, Inc. (INVA) common shares, or 15.4%, as of September 30, 2026. BlackRock reported sole voting power over 10,924,497 shares and sole dispositive power over 11,138,961 shares, with zero shared voting or dispositive power. The filing identifies iShares Core S&P Small-Cap ETF as having an interest in more than 5% of Innoviva's outstanding common stock.
Innoviva, Inc. (INVA) reported an insider equity-related transaction by Chief Accounting Officer Marianne Zhen. On 2026-08-20, 1,127 shares of common stock were disposed of at $21.00 per share through shares withheld by the company to satisfy income tax withholding obligations tied to quarterly vesting of previously granted employee equity grants. After this tax-withholding transaction, Zhen directly held 56,389 shares of Innoviva common stock.
Innoviva, Inc. (INVA) reported an insider transaction by Chief Financial Officer Stephen Basso. On August 20, 2026, 558 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations related to the quarterly vesting of previously granted employee equity awards. Following this withholding, Basso beneficially owns 88,013 shares of Innoviva common stock held directly.
Innoviva, Inc. (INVA) reported an insider tax-related share withholding by Chief Executive Officer and director Pavel Raifeld. On 2026-08-20, 1,130 shares of common stock were disposed of at $21.00 per share to satisfy income tax withholding obligations tied to the quarterly vesting of previously granted equity awards. Following this withholding transaction, Raifeld directly owned 284,799 shares of Innoviva common stock.
Innoviva, Inc. reported Q2 2026 total revenue of $119.6 million, up from $100.3 million a year earlier, with income from operations of $50.9 million. The quarter nevertheless showed a net loss of $83.4 million, mainly from a $131.8 million unrealized loss on Armata equity holdings and $29.2 million losses on other investments.
For the first six months of 2026, total revenue reached $217.6 million and net income was $103.2 million, compared with $188.9 million in revenue and $17.1 million in net income in 2025, helped by earlier-period fair‑value gains and higher net product sales, particularly GIAPREZA and XACDURO.
Cash and cash equivalents were $570.4 million as of June 30, 2026, against $258.5 million of long‑term convertible notes, and stockholders’ equity was $1.23 billion. The company repurchased 2.37 million shares in the first half of 2026 for approximately $51.8 million.
Innoviva, Inc. reported second quarter 2026 results featuring higher revenue but a net loss driven by investment fair value movements. Total revenue for the quarter ended June 30, 2026 was $119.6 million, with royalty revenue, net of capitalized fee amortization, of $56.3 million, net product sales of $51.8 million, and license and other revenue of $11.5 million. Income from operations was $50.9 million, but large negative changes in the fair values of equity method investments of $(131.8) million and equity and long-term investments of $(29.2) million led to a net loss of $(83.4) million, compared with net income of $63.7 million a year earlier.
For the first six months of 2026, total revenue was $217.6 million and net income was $103.2 million, indicating strong year-to-date profitability despite the second-quarter loss. Cash and cash equivalents were $570.4 million as of June 30, 2026, supported by $87.3 million of net cash provided by operating activities in the first half. The Innoviva Specialty Therapeutics platform generated U.S. net product sales of $36.6 million in the quarter, representing 26% year-over-year growth, and management stated it remains on track to achieve at least $150 million in IST U.S. net product sales in 2026. The company also highlighted a commercialization and licensing agreement with Dr. Reddy’s Laboratories for XACDURO in emerging markets and the launch of Nortiva Bio, a wholly owned strategic healthcare asset focused on extended-release oral drug delivery.
Vanguard Capital Management LLC, together with certain affiliates, reports beneficial ownership of 3,704,185 shares of Innoviva Inc common stock on a Schedule 13G. This position represents 5.01% of Innoviva’s outstanding common stock.
Vanguard reports sole voting power over 546,132 shares and sole dispositive power over all 3,704,185 shares, with no shared voting or dispositive power. Dividends and sale proceeds are generally for Vanguard-managed funds and accounts, and no other single person has an interest exceeding 5% of the class.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported routine equity compensation activity. On May 15, 2026, he acquired 1,123 shares of common stock through the company’s Employee Stock Purchase Plan. On May 20, 2026, 559 shares were withheld to cover income taxes on vesting of earlier equity awards, leaving him with 88,571 shares held directly. The withholding is not an open-market sale and reflects tax obligations tied to prior grants.